International Masterclass ‘Psoriasis – Update on Treatment Options’
19 June @ 7:30 pm - 8:30 pmFree
Please join world-renowned International Psoriasis Council Councillor and Key Opinion Leader in psoriasis, Professor Richard Warren, as he discusses the explosion of therapeutic options over the last two decades in psoriasis.
His presentation will explore what’s currently available, what’s about to become available, and how to use them appropriately.
The session will be presented via Zoom and live-streamed at a dinner meeting organised by our event partner Janssen at Postmaster Hotel, 186 High St, Kew VIC 3101.
Please see the agenda for the dinner meeting below. The Zoom meeting will commence at 7:30pm:
Arrival with entrée served
Professor Richard Warren presents (first five mins Tremfya update by Dr Rebecca Sweet)
Dinner followed by dessert
Professor Richard Warren
BSc MBChB MRCP PhD
Professor Warren is a consultant dermatologist and Lead of the Dermatology Centre at the University of Manchester. He graduated from Liverpool University with a first-class Honours degree in pharmacology and gained his medical degree with Honours one year later. His work in dermatology has focused on complex disease genetics, investigating novel therapies in the treatment of inflammatory skin diseases and precision medicine. He has received national and international awards for his research and supervised many award-winning PhD students. His other roles include Academic Vice President of the British Association of Dermatologists, Lead for early phase research for the Northern Care Alliance and Director of a successful dermatology trials unit which has been pivotal in delivering many novel therapies to clinic.
Professor Warren has acted as Global Chief Investigator (CI) on more than 10 phase 1-3 studies and is the current CI on the British Association of Dermatologists Biologics and Immunomodulators Registry, widely considered the premier drug safety registry in psoriasis worldwide.
He is also a member of several national committees, including critical roles on defining those at greatest risk with immune mediated disease on systemic therapies during the COVID pandemic. He holds the current EU Editor of the Journal of Dermatology and Therapy post and sits on five editorial boards.
He has published widely in the field of dermatology with more than 270 papers including 1st author original articles in The Lancet and New England Journal of Medicine. His current H-index is 58, with over 35 publications in each of the last three years.